Kite Pharma and Chinese biotech Pregene agreed to a high‑value collaboration focused on in vivo CAR‑T therapies, with headline potential in the low‑to‑mid‑$1‑billion range and substantial upfronts for Pregene’s platform. The deal combines Kite’s clinical and commercial muscle with Pregene’s in‑vivo delivery and manufacturing capabilities to accelerate next‑generation CAR approaches for oncology and autoimmune indications. Companies emphasized the deal’s scope — from R&D through potential global commercialization — and framed it as a bet on in‑patient generation of engineered immune cells to improve scalability and access relative to ex vivo CAR‑T.